MvfR Controls Tolerance to Polymyxin B by Regulating rfaD in Pseudomonas aeruginosa

Antibiotic resistance imposes a considerable challenge for the treatment of P. aeruginosa infections. Polymyxins are the last-resort antibiotics for the treatment of multidrug-resistant P. aeruginosa infections. ABSTRACT Polymyxins are currently the last-resort antibiotics for the treatment of multidrug-resistant Gram-negative bacterial infections. To expand the understanding of the intrinsic resistance mechanism against polymyxins, a laboratory strain of Pseudomonas aeruginosa PAO1 was subjected to serial passage in the presence of sublethal doses of polymyxin B over a period of 30 days. By whole-genome sequencing of successively isolated polymyxin B-resistant isolates, we identified a frameshift mutation (L183fs) in the mvfR gene that further increased polymyxin resistance in the pmrB mutant background. A ΔmvfR mutation alone showed higher tolerance to polymyxin B due to altered lipopolysaccharide (LPS) on the surface of bacterial cells, which decreases its outer membrane permeability. In the ΔmvfR mutant, polymyxin B treatment caused the upregulation of rfaD, the gene involved in LPS core oligosaccharide synthesis, which is responsible for polymyxin tolerance. To the best of our knowledge, this is the first report of mvfR mutation conferring polymyxin resistance in P. aeruginosa via increased integrity of bacterial outer membrane. IMPORTANCE Antibiotic resistance imposes a considerable challenge for the treatment of P. aeruginosa infections. Polymyxins are the last-resort antibiotics for the treatment of multidrug-resistant P. aeruginosa infections. Understanding the development and mechanisms of bacterial resistance to polymyxins may provide clues for the development of new or improved therapeutic strategies effective against P. aeruginosa. In this study, using an in vitro evolution assay in combination with whole-genome sequencing, we demonstrated that MvfR controls tolerance to polymyxin B by regulating the rfaD gene in P. aeruginosa. Our results reveal a novel mechanism employed by P. aeruginosa in the defense against polymyxin antibiotics.

[1]  P. Tulkens,et al.  Activity of Moxifloxacin Against Biofilms Formed by Clinical Isolates of Staphylococcus aureus Differing by Their Resistant or Persister Character to Fluoroquinolones , 2021, Frontiers in Microbiology.

[2]  B. Hoogenboom,et al.  Phase separation in the outer membrane of Escherichia coli , 2021, Proceedings of the National Academy of Sciences.

[3]  T. Tenson,et al.  Uropathogenic Escherichia coli Shows Antibiotic Tolerance and Growth Heterogeneity in an In Vitro Model of Intracellular Infection , 2021, Antimicrobial agents and chemotherapy.

[4]  G. Larrouy-Maumus,et al.  Colistin resistance in Escherichia coli confers protection of the cytoplasmic but not outer membrane from the polymyxin antibiotic , 2021, bioRxiv.

[5]  L. Hoffmann,et al.  A tunable anthranilate-inducible gene expression system for Pseudomonas species , 2020, Applied microbiology and biotechnology.

[6]  C. Arrieumerlou,et al.  ADP-heptose: a bacterial PAMP detected by the host sensor ALPK1 , 2020, Cellular and Molecular Life Sciences.

[7]  Liang Yang,et al.  Molecular genetic analysis of an XDR Pseudomonas aeruginosa ST664 clone carrying multiple conjugal plasmids. , 2020, The Journal of antimicrobial chemotherapy.

[8]  Youjun Feng,et al.  Genetic and Biochemical Mechanisms for Bacterial Lipid A Modifiers Associated with Polymyxin Resistance. , 2019, Trends in biochemical sciences.

[9]  B. Valot,et al.  Production of Norspermidine Contributes to Aminoglycoside Resistance in pmrAB Mutants of Pseudomonas aeruginosa , 2019, Antimicrobial Agents and Chemotherapy.

[10]  M. Trent,et al.  Pushing the envelope: LPS modifications and their consequences , 2019, Nature Reviews Microbiology.

[11]  Thomas B. Clarke,et al.  Colistin kills bacteria by targeting lipopolysaccharide in the cytoplasmic membrane , 2018, eLife.

[12]  Jian Sun,et al.  Towards Understanding MCR-like Colistin Resistance. , 2018, Trends in microbiology.

[13]  T. Owens,et al.  Novobiocin Enhances Polymyxin Activity by Stimulating Lipopolysaccharide Transport. , 2018, Journal of the American Chemical Society.

[14]  R. Hartmann,et al.  In-depth Profiling of MvfR-Regulated Small Molecules in Pseudomonas aeruginosa after Quorum Sensing Inhibitor Treatment , 2017, Front. Microbiol..

[15]  Shouguang Jin,et al.  In vivo Host Environment Alters Pseudomonas aeruginosa Susceptibility to Aminoglycoside Antibiotics , 2017, Front. Cell. Infect. Microbiol..

[16]  L. Rahme,et al.  Evidence for Direct Control of Virulence and Defense Gene Circuits by the Pseudomonas aeruginosa Quorum Sensing Regulator, MvfR , 2016, Scientific Reports.

[17]  P. Lu,et al.  Mutation of the Enterohemorrhagic Escherichia coli Core LPS Biosynthesis Enzyme RfaD Confers Hypersusceptibility to Host Intestinal Innate Immunity In vivo , 2016, Front. Cell. Infect. Microbiol..

[18]  Ofer Fridman,et al.  Distinguishing between resistance, tolerance and persistence to antibiotic treatment , 2016, Nature Reviews Microbiology.

[19]  Xavier Borrisé,et al.  Creation of guiding patterns for directed self-assembly of block copolymers by resistless direct e-beam exposure , 2015, Advanced Lithography.

[20]  S. Fang,et al.  Antibacterial Mechanisms of Polymyxin and Bacterial Resistance , 2015, BioMed research international.

[21]  K. Ko,et al.  Mutations and expression of PmrAB and PhoPQ related with colistin resistance in Pseudomonas aeruginosa clinical isolates. , 2014, Diagnostic microbiology and infectious disease.

[22]  Brittany D. Needham,et al.  Fortifying the barrier: the impact of lipid A remodelling on bacterial pathogenesis , 2013, Nature Reviews Microbiology.

[23]  D. Kwon,et al.  Differential Role of Two-Component Regulatory Systems (phoPQ and pmrAB) in Polymyxin B Susceptibility of Pseudomonas aeruginosa. , 2012, Advances in microbiology.

[24]  Samuel I. Miller,et al.  PmrB Mutations Promote Polymyxin Resistance of Pseudomonas aeruginosa Isolated from Colistin-Treated Cystic Fibrosis Patients , 2011, Antimicrobial Agents and Chemotherapy.

[25]  Samuel I. Miller,et al.  PhoQ Mutations Promote Lipid A Modification and Polymyxin Resistance of Pseudomonas aeruginosa Found in Colistin-Treated Cystic Fibrosis Patients , 2011, Antimicrobial Agents and Chemotherapy.

[26]  J. Lam,et al.  Review: Lipopolysaccharide biosynthesis in Pseudomonas aeruginosa , 2009, Innate immunity.

[27]  C. Raetz,et al.  Lipid A modification systems in gram-negative bacteria. , 2007, Annual review of biochemistry.

[28]  A. Zaborin,et al.  Dynorphin Activates Quorum Sensing Quinolone Signaling in Pseudomonas aeruginosa , 2007, PLoS pathogens.

[29]  L. Rahme,et al.  MvfR, a key Pseudomonas aeruginosa pathogenicity LTTR‐class regulatory protein, has dual ligands , 2006, Molecular microbiology.

[30]  J. Turnidge,et al.  Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. , 2006, The Lancet. Infectious diseases.

[31]  E. Estenssoro,et al.  Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study , 2005, Intensive Care Medicine.

[32]  M. Falagas,et al.  Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. , 2005, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[33]  H. Nikaido.  Molecular Basis of Bacterial Outer Membrane Permeability Revisited , 2003, Microbiology and Molecular Biology Reviews.

[34]  S. Ealick,et al.  The crystal structure of ADP-L-glycero-D-mannoheptose 6-epimerase: catalysis with a twist. , 2000, Structure.

[35]  T. Mattila-Sandholm,et al.  Fluorometric assessment of Gram‐negative bacterial permeabilization , 2000, Journal of applied microbiology.

[36]  H. Schweizer,et al.  A broad-host-range Flp-FRT recombination system for site-specific excision of chromosomally-located DNA sequences: application for isolation of unmarked Pseudomonas aeruginosa mutants. , 1998, Gene.

[37]  D. Stein,et al.  A mutation in the Neisseria gonorrhoeae rfaD homolog results in altered lipooligosaccharide expression , 1995, Journal of bacteriology.

[38]  M. Vaara.  Outer membrane permeability barrier to azithromycin, clarithromycin, and roxithromycin in gram-negative enteric bacteria , 1993, Antimicrobial Agents and Chemotherapy.

[39]  P. Taylor.  Bactericidal and bacteriolytic activity of serum against gram-negative bacteria , 1983 .

[40]  L. Leive,et al.  Two mutations which affect the barrier function of the Escherichia coli K-12 outer membrane , 1979, Journal of bacteriology.

[41]  J. Boyce,et al.  Mechanisms of Polymyxin Resistance. , 2019, Advances in experimental medicine and biology.

[42]  P. Wayne.  PERFORMANCE STANDARDS FOR ANTIMICROBIAL SUSCEPTIBILITY TESTING, NINTH INFORMATIONAL SUPPLEMENT , 2008 .

[43]  H. Schweizer,et al.  mini-Tn7 insertion in bacteria with single attTn7 sites: example Pseudomonas aeruginosa , 2006, Nature Protocols.

[44]  C. Whitfield,et al.  Lipopolysaccharide endotoxins. , 2002, Annual review of biochemistry.

[45]  M. Ferraro.  Performance standards for antimicrobial susceptibility testing , 2001 .